Primary Prophylaxis for Spontaneous Bacterial Peritonitis (SBP)
Patient Selection for Primary Prophylaxis
- The European Association for the Study of the Liver recommends primary prophylaxis for high-risk cirrhotic patients with ascites who have low ascitic fluid protein (<15 g/L) combined with advanced liver disease or impaired renal function, with norfloxacin 400 mg daily 1, 2, 3
- Patients with ascitic fluid protein <15 g/L and one of the following conditions should receive primary prophylaxis: Child-Pugh score ≥9 with serum bilirubin ≥3 mg/dL, impaired renal function, or hyponatremia (serum sodium ≤130 mEq/L) 1, 2, 3, 4, 5
Recommended Antibiotic Regimens
- The American Association for the Study of Liver Diseases recommends norfloxacin 400 mg orally once daily as the first choice for primary prophylaxis of SBP 5, 6
- Ciprofloxacin 500 mg orally once daily is an alternative, especially in regions where norfloxacin availability is limited 4, 7
Evidence Supporting Prophylaxis
- Primary prophylaxis with norfloxacin reduces the one-year probability of developing SBP (7% vs. 61%) and improves three-month survival probability (94% vs. 62%) 1, 2, 5, 7
- Norfloxacin also reduces the risk of hepatorenal syndrome (28% vs. 41%) 1, 3
Important Considerations and Pitfalls
- Fluoroquinolones carry risks of side effects, including tendon inflammation and damage, particularly in patients with renal impairment 2, 7
- Long-term antibiotic use can lead to bacterial resistance and increased risk of Clostridium difficile infection 1, 6
Monitoring Recommendations
- Regular clinical assessment for signs of SBP (fever, abdominal pain, encephalopathy) and periodic monitoring of renal function are recommended 1, 9, 7
- Vigilance for adverse effects of fluoroquinolones and consideration of diagnostic paracentesis if clinical deterioration occurs are also recommended 2, 4, 7, 9